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A B S T R A C T
We previously demonstrated that lipopolysaccharide (LPS) administered intraperitoneally (i.p.) to pregnant
Wistar rat dams, at embryonic days 15 and 16 (E15/16), induced a decrease of baseline locomotor activity and
diminished reactivity to amphetamine in adult female oﬀspring. In the present study we aimed to assess the
duration of LPS-induced maternal immune activation (MIA) and investigate possible changes in levels of main
neurotransmitters in fetal brain during MIA. We hypothesized that the observed behavioral changes may be
linked with MIA-induced disturbance of prenatal GABAergic system development, especially with α5 GABAA
receptors (α5GABAARs), expression of which takes place between E14 and E17. Thereafter, we set to investigate
if later potentiation of α5GABAARs in oﬀspring’s preadolescence (from postnatal day 22–28) could prevent the
deﬁcit in locomotor reactivity to amphetamine observed in adulthood, at postnatal day P60. The elevation of IL-
6 in amniotic ﬂuid 6 h after LPS treatment (100 μg/kg, i.p.) at E15 was concurrent with a signiﬁcant increase of
GABA and decrease of glutamate concentration in fetal brain. Moreover, repeated administration of MP-III-022,
a selective positive allosteric modulator of α5GABAARs, at a dose (2 mg/kg daily, i.p.) derived from a separate
pharmacokinetic study, prevented the LPS-induced decrease in locomotor reactivity to amphetamine (0.5 mg/
kg, i.p.) in adult females. These results were not mirrored in the parallel set of experiments with male oﬀspring
from LPS-treated rats. The results suggest that pharmacological potentiation of α5GABAARs activity in pre-
adolescence may ameliorate at least some of adverse consequences of exposure to MIA in utero.
1. Introduction
Maternal immune activation (MIA) is one of the most investigated
prenatal inﬂuences with potentially harmful eﬀects on brain develop-
ment. Epidemiological studies have linked the emergence of schizo-
phrenia and several other neurodevelopmental disorders with an in-
creased incidence of MIA caused by bacterial or viral infections during
pregnancy (Brown and Derkits, 2010). MIA is suggested to lead to a
disbalance between pro- and anti-inﬂammatory cytokines in the fetal
brain, which may ultimately impact in utero neurodevelopment and
result in sustained long-lasting alterations in postnatal brain (Meyer
et al., 2009, 2011). Several animal models of prenatal exposure to MIA,
designed to mimic behavioral symptoms and elucidate pathophysiolo-
gical mechanisms underlying the disorders related to abnormal fetal
brain development, diﬀer with respect to the challenging agents and the
time of exposure (Harvey and Boksa, 2012).
Lipopolysaccharide (LPS), a cell wall component of gram negative
bacteria, induces febrile response and cytokine release when adminis-
tered intraperitoneally to pregnant rodents. Due to a signiﬁcant varia-
bility in LPS exposure protocols, a diversity of ﬁndings was reported,
describing acute changes in fetal compartment, as well as behavioral
symptoms and morphological alterations in oﬀspring. Nevertheless, the
changes observed in a number of studies on LPS-treated rodents are
consistent with those seen in schizophrenia patients, including
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behavioral changes or postmortem ﬁndings in brain tissue (reviewed in
Boksa, 2010). A growing body of evidence supports the concept that
development of GABAergic system may be a major convergence point
for both genetic and environmental susceptibility factors for schizo-
phrenia, as reviewed by Schmidt and Mirnics (2015). Oskvig et al.
(2012) showed that a substantial number of GABA-related genes are
acutely dysregulated by LPS treatment at E15, such as genes for GAD
(glutamate decarboxylase) 67 and GAD65, as well as those which ex-
pression enables the hippocampal and cortical migration (Dlx1, 2, 5,
and 6) (Cobos et al., 2005). In line with reports on reduction in mRNA
and protein for GAD67 (e.g. Benes et al., 2007) and reelin (e.g.
Eastwood and Harrison, 2006) in various brain regions, including the
hippocampus, of schizophrenia subjects, Nouel et al. (2012) found that
LPS (100 μg/kg) treatment of pregnant rat dams at embryonic day (E)
15 and 16 led to a reduction of GAD67-immunoreactive and reelin-
immunoreactive hippocampal neurons in preadolescent rat oﬀspring.
Moreover, an identical protocol of exposure to LPS resulted in a de-
creased prepulse inhibition of acoustic startle in adult oﬀspring, in-
dicating the deﬁcits in sensorimotor gating, which is a ﬁnding con-
sistent with schizophrenia (Fortier et al., 2007). Nouel et al. (2012)
suggested that the changes in prepulse inhibition, as a form of behavior
partially modulated by the hippocampus, may be inﬂuenced by al-
terations in levels of GABA or reelin, as key neurochemical components
of hippocampal function. The postnatal persistence of developmental
MIA-induced changes in GABAergic system is still to be unequivocally
assessed. For example, in the hippocampus, LPS treatment on E15/16
has not only immediate eﬀects on dentate cells, but also results in a
decreased proliferation and survival of dentate cells generated at
postnatal day (P) 14, whereas adult hippocampal neurogenesis at P60
was not aﬀected (Cui et al., 2009).
We have previously shown that LPS (100 μg/kg) administered to
pregnant Wistar dams at E15/16 resulted in a signiﬁcantly diminished
baseline locomotor activity and reduced locomotor response to am-
phetamine in adult female oﬀspring (P60), while the changes in adult
males were less pronounced (Batinić et al., 2016); the reduction in
spontaneous and amphetamine-induced locomotor activity was also
observed in studies using the similar protocol of LPS exposure in rats
(Harvey and Boksa, 2014a, 2014b). Importantly, the time of LPS
treatment in our protocol (E15/16) correlates with the emergence of α5
GABAA receptors (α5GABAARs) and migration of interneurons (Lauri
et al., 1992). In the period between E14 and E17, the α5 subunit of
GABAA receptor is the only one among all six α subunits that is in the
process of expression in important brain structures: fetal cortex, fetal
thalamus and fetal hippocampus (Lauri et al., 1992). Thus, we hy-
pothesized that behavioral alterations observed in our model may at
least partly derive from LPS-mediated disturbance of α5GABAARs
function, possibly occurring in the developing brain at E15/16. We
aimed to investigate whether the onset of behavioral symptoms in
adulthood may be aﬀected by preadolescent modulation of α5G-
ABAARs, accomplished after GABA excitatory/inhibitory shift (Ben-Ari,
2002) and relocalization from the cell bodies to the dendritic layers
have taken place (Ramos et al., 2004). To potentiate the activity of
α5GABAARs in the settings of decreased GABA-ergic neurotransmission
demonstrated in the hippocampus of LPS-exposed oﬀspring at P14, and
especially P28 (Nouel et al., 2012), we repeatedly administered MP-III-
022, a thoroughly proﬁled selective positive allosteric modulator (PAM)
(Stamenić et al., 2016), during the fourth week of postnatal develop-
ment.
2. Materials and methods
2.1. Animals
Male and female Wistar rats were obtained from Military Farm
(Belgrade, Serbia) at the age of two months, weighting 180–220 g, and
were housed separately in male and female animal rooms. The rats were
housed in transparent plastic cages and had free access to food pellets
and tap water. The temperature of the animal room was 22 ± 1∘C, the
relative humidity 40–70%, the illumination 120 Lx, and the 12/12 h
light/dark period (light on at 6:00 h). All handling and testing took
place during the light phase of the diurnal cycle. All procedures in the
study conformed to EEC Directive 86/609 and were approved by the
Ethical Committee on Animal Experimentation of the Faculty of
Pharmacy in Belgrade.
2.2. LPS treatment
The procedure of handling and treatment of animals was replicated
from our previous study (Batinic et al., 2016). After joining a male and
female rat in a single cage, vaginal smears were taken daily at 9 am and
if found positive for spermatozoa females were separated from the
males. To avoid a social isolation context, pregnant dams were housed
three per cage until gestation day 19 and then individually until de-
livery. On gestation (embryonic) days 15 and 16 (E15/16) pregnant
dams were treated intraperitoneally either with LPS (from Escherichia
coli, serotype 0111:B4, Sigma L2630) at a dose of 100 g/kg per day, or
with 0.9% saline (2 mL/kg per day). After delivery, oﬀspring were left
with their mothers undisturbed until postnatal day 21, and then were
weaned, separated by gender and housed up to ﬁve and not less than
three per cage. The pups from diﬀerent litters were not mixed. In the
further text, oﬀspring rats born to dams treated with LPS will be re-
ferred to as LPS oﬀspring or LPS males or LPS females.
2.3. Cytokine determination
For the determination of cytokines at both E15 and E16, pregnant
dams of separate cohorts were sacriﬁced 2 h and 6 h after LPS or SAL
treatment, as suggested by Bell et al. (2004). The following samples
were harvested: dam’s blood, placenta, amniotic ﬂuid, and fetal brain.
To determine possible cytokine induction in adult oﬀspring of both
genders, their blood and brains were taken at P60. Blood was collected
in heparinized tubes, centrifuged at 1000g for 10 min and plasma was
collected. The placenta and brain tissue samples were placed in tubes
with buﬀer (50 mM Tris-HCl, 0,6 M NaCl, 0,2% Triton X-100, 0,5% BSA
and protease inhibitors), then homogenized and centrifuged at 14000g
at 4 °C, and supernatants were collected. Plasma, amniotic ﬂuid and
supernatants were stored at − 80 °C until analysis. Cytokine assays
using enzyme-linked immunosorbent assay (ELISA) kits (Rat TNF-alpha
ELISA Ready-SET-Go!®, eBioscence, USA and IL-6 ELISA Kit, Rat, Life
Technologies, USA) were processed according to the manufacturer’s
instructions. The detection limits were 16 pg/mL for TNF-α and
23.5 pg/mL for IL-6.
2.4. Neurotransmiters quantiﬁcation
Five neurotransmitters: glutamate (GLU), gamma-Aminobutyric
acid (GABA), dopamine (DA), noradrenaline (NA) and serotonin (5-HT)
were determined using the protocol described in Huang et al. (2014)
with additional determination of acetylcholine (Ach), in fetal brain in
total and selected parts of adult brain. Calibration solutions for acet-
ylcholine were the same concentration range as for dopamine, nora-
drenaline and serotonin.
Whole fetal brains were collected 2 h and 6 h after LPS or SAL
treatment at E15 and E16, while adult brain tissues (prefrontal cortex,
dorsal striatum, nucleus accumbens and ventral hippocampus) were
sampled from experimentally naive rats decapitated at P60. Brains of
adult animals were instantly removed from the skull, washed with ice-
cold saline and put into the cold brain matrices (Zivic Instruments).
Brain sections were cut according to Paxinos-Watson atlas, and re-
moved from the matrix onto ice-cold pad to isolate the analyzed
structures. The whole hippocampus was separated from the rest of its
brain section and ventral two-ﬁfths of the structure were cut. Samples
B. Batinić et al. International Journal of Developmental Neuroscience 61 (2017) 31–39
32
were immediately weighted, frozen in liquid nitrogen and afterwards
collected and kept at −80 °C until analysis. Ice cold methanol (0.1%
formic acid) was added in a ratio 1:12.5 (tissue (mg): methanol (μL))
and the sample was homogenized. A 100 μL of homogenate was diluted
3.2 × (in total, 40 × dilution) with 175.2 μL methanol (0.1% formic
acid) and 44.8 μL of internal standard (30 μg/mL benzylamine). The
samples were then vortexed and centrifuged at 18,000g for 10 min at
4 °C. The supernatant was evaporated to dryness under nitrogen stream.
The residue was reconstituted with 350 μL of mobile phase (0.1%
formic acid in water/acetonitrile, 98:2, v/v), and put into the LC–MS/
MS system for analysis.
LC–MS/MS analyses were performed using an Accela LC system
coupled to a triple-quadrupole mass spectrometer (Thermo Scientiﬁc
TSQ Quantum Access Max, San Jose, CA, USA) with heated electrospray
ionization (HESI). The optimized parameters of the mass analyzer’s
interface were as follows: positive-ion mode; spray voltage, 4000 V;
vaporizer temperature, 325 °C; sheath gas (nitrogen) pressure, 30; aux
gas (nitrogen) pressure, 10; ion sweep gas (nitrogen) pressure, 1.0;
capillary temperature, 300 °C; scan time, 0.2 s; Q1 (FWHM), 0.70;
collision gas (argon) pressure, 1.5 mTorr. Analytes were monitored by
selected reaction monitoring (SRM) mode as follows: GABA m/z 104→
87 (CE, 10 V), Ach m/z 146→ 87 (CE, 14 V), GLU m/z 148→ 84 (CE,
16 V), DA m/z 154→ 137 (CE, 8 V), NE m/z 170→ 152 (CE, 5 V), 5-HT
177→ 160 (CE, 8 V) and benzylamine m/z 108→ 91 (CE, 10 V).
2.5. Kinetics of repeated MP-III-022 administration
In our previous paper (Stamenić et al., 2016) we established that the
2.5 mg/kg (i.p.) dose of MP-III-022, given acutely, exerts selective po-
tentiation of α5GABAARs and produces no muscle relaxation, ataxia,
sedation, or an inﬂuence on the anxiety level. To obtain kinetics of MP-
III-022 (2.5 mg/kg) during 7 days of repeated administration, we used a
separate cohort of pups, delivered from untreated Wistar dams. MP-III-
022 (synthesized at the Department of Chemistry and Biochemistry,
University of Wisconsin-Milwaukee) was suspended in a solvent (SOL)
containing 85% distilled water, 14% propylene glycol and 1% Tween-
80. We administrated MP-III-022 at a dose of 2.5 mg/kg (i.p.) once
daily from P22 to P28, to both female and male pups. At ﬁve diﬀerent
time points (20 min after the 1st dose, 24 h after the 1st dose, 20 min
after the 3rd dose, 20 min after the 7th dose, and 24 h after the 7th
dose) we sacriﬁced 3 rats per gender, per time point. Rats were de-
capitated and brains were weighed, homogenized in 2 mL of methanol
and centrifuged at 3400g for 20 min. To determine the concentration of
MP-III-022 in supernatants of brain tissue homogenates, MP-III-022 was
extracted from these samples by solid phase extraction, using Oasis HLB
cartridges (Waters Corporation, Milford, Massachusetts). The procedure
of sample preparation and determination of MP-III-022 by ultra-
performance liquid chromatography–tandem mass spectrometry
(UPLC–MS/MS) with Thermo Scientiﬁc Accela 600 UPLC system con-
nected to a Thermo Scientiﬁc TSQ Quantum Access MAX triple quad-
rupole mass spectrometer (Thermo Fisher Scientiﬁc, San Jose, Cali-
fornia), equipped with an electrospray ionization (ESI) source, has been
already described in detail (Stamenić et al., 2016)
2.6. MP-III-022 administration
For postnatal treatment in the main experiment, pups were divided
by gender (male or female), prenatal treatment (LPS or SAL) and
postnatal treatment (MP-III-022 or SOL) into eight testing groups in
total. After analyzing kinetics of MP-III-022 dosed at 2.5 mg/kg during
7 days of repeated intraperitoneal administration, we decided to use a
20% lower dose (2 mg/kg) due to observations commented in the re-
sults Section 3.3. MP-III-022 or SOL were repeatedly administered
(5 mL/kg, i.p.) using 26 gauge needles, once daily for 7 days (P22 to
P28), at the same time around 14:00 h. Each day before the treatment
pups were weighted, and the average weight recorded was from around
25 g (P22) to 50 g (P28).
2.7. Baseline and amphetamine induced locomotor activity
As detailed in Batinić et al. (2016), locomotor activity testing was
conducted in four blurred plexiglas chambers (40 × 25 × 35 cm)
under dim red light (20 Lx) and tested animals weighted 180–220 g.
Testing was performed in three consecutive trials. In the ﬁrst trial, a
single rat was placed in the apparatus for 30 min of habituation and
baseline locomotor activity was recorded. This was followed by saline
application (i.p.) and rat’s activity was recorded in the second 30-min
trial to examine whether injection stressor per se induced a locomotor
response. Finally, the third trial started with an intraperitoneal ad-
ministration of 0.5 mg/kg of amphetamine (Sigma-Aldrich) and loco-
motor activity was recorded for 60 min. Before testing the next group of
animals olfactory traces were removed using diluted ethanol. Besides
the total distance travelled, behavior was analyzed by dividing the lo-
comotor activity data into 10-min bins. Behavior was recorded using
camera mounted on the ceiling of the testing room and connected to a
computer equipped with AnyMaze software (Stoelting Co.).
2.8. Experimental design
The design of the present study is graphically represented on an
experimental timeline in Fig. 1.
2.9. Statistical analysis
Concentrations of each neurotransmitter in fetal brains were sta-
tistically analyzed using Student’s t-test to compare samples from LPS-
and SAL-treated dams, and separate analyses were done for each of four
time points: 2 h and 6 h after treatment on both, E15 and E16. Brain
concentrations of each neurotransmitter in a speciﬁc brain tissue at P60
were analyzed using two-way ANOVA with LPS and MP-III-022 as be-
tween-subject factors, separately for male and female rats.
Data from AILA testing obtained from male and female rats were
analyzed separately, and values from 2 or 3 animals within a litter were
averaged and a single value per litter was used in statistical analysis as
suggested by Lazic and Essioux (2013). We used a three-way ANOVA
with repeated measures (LPS and MP-III-022 treatments as two be-
tween-subject factors and time as within-subject factor). If signiﬁcant
(p < 0.05), the main eﬀect was further analyzed using pairwise
Fig. 1. Experimental design. Pregnant dams were
treated with LPS or saline on embryonic days 15 and
16 (E15/16), while oﬀspring were treated with MP-
III-022 or solvent repeatedly from postnatal day
22–28 (P22-P28). Cytokine (CK) and neuro-
transmitter (NT) analysis were conducted on E15/16
and P60. Baseline and amphetamine induced loco-
motor activity (AILA) was recorded on P60.
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multiple comparison procedures (Student–Newman–Keuls method). A
trend denotes p values between 0.05 and 0.1. Data were processed
using SPSS Statistics 20 (IBM).
3. Results
3.1. Cytokine determination in dams’ and fetal tissues
Cytokine concentrations in samples analyzed 2 h or 6 h after LPS
treatment on E15 and E16 are presented in Table 1. In the samples
taken from dams treated with SAL, no detectable levels of cytokines
were found. Unfortunately, in solid tissues (placenta and fetal brain) we
were not unable to obtain interpretable results of IL-6 concentrations.
3.2. Neurotransmitter quantiﬁcation in fetal rat brain
Fetal brain concentrations of all neurotransmitters are presented in
Table 2. Twenty-four Student’s t-test calculations in total were con-
ducted to analyze concentrations of all six neurotransmitters at four
time points; only reports bearing signiﬁcant diﬀerences are presented in
this section. The LPS treatment on E15 induced a signiﬁcant increase of
GABA concentration (t(16) = 2.655, p = 0.017) and a signiﬁcant de-
crease in glutamate concentrations (t(16) =−2.346, p = 0.032) in
fetal brain 6 h after treatment, in comparison to control tissue samples.
Of note, a trend of decrease in glutamate concentration (t(13)
=−1.801, p = 0.095) was found at the previous time point, 2 h after
treatment on E15.
3.3. MP-III-022 kinetics
The total and estimated free brain concentrations of MP-III-022,
dosed at 2.5 mg/kg and administered to pups during 1, 3 or 7 days from
P22, are presented in Table 3. As the maximum estimated free brain
concentrations obtained in the present kinetic study using a dose of
2.5 mg/kg were at the level of 100 nM, which is connected with a slight
positive modulation of α2 and α3 GABAA receptors (Stamenić et al.,
2016), we opted to use in the treatment protocol a 20% lower dose of
MP-III-022 (2 mg/kg). Based on the elaborate analysis presented in
Stamenić et al., 2016, and the current pharmacokinetic study in pups,
this dose is expected to enable a protracted slight to moderate positive
modulation of GABAA receptors containing the α5 subunit without a
concomitant modulation of other receptor subtypes.
3.4. Baseline and amphetamine induced locomotor activity
The results of locomotor performance of female and male adult
animals are presented, respectively, in Figs. 2 and 3. Six 3-way RM
ANOVA calculations were done in total to analyze eﬀects of LPS and
MP-III-022 across time in each of three testing trials, separately for male
and female rats. General description of signiﬁcance of between-subject
factors (LPS and MP-III-022) in respective analyses is presented in panel
A, while the results of pairwise multiple comparison procedures are
shown in graphs B–F of Figs. 2 and 3. The exact values of statistical
analysis are presented in Supplementary Table S1.
Table 1
Concentrations of TNF-α and IL6 in dam’s blood, placenta, amniotic ﬂuid and fetal brain 2 h and 6 h after of LPS treatment on E15 and E16; after SAL treatment no detectable levels of
cytokines were found in any sample analyzed. Samples were taken from 3 dams per treatment at each time point. Data are presented as mean value ± SD (pg/mL), except the values
below the limit of detection (ND).
Cytokine Tissue Time point
E15 (2 h) E15 (6 h) E16 (2 h) E16 (6 h)
TNF-α Dam’s blood 137.05 ± 71.12 17.22 ± 4.91 ND ND
Placenta 145.71 ± 63.08 33.36 ± 12.67 18.33 ± 6.73 ND
Amniotic ﬂuid ND ND ND ND
Fetal brain ND ND ND ND
IL-6 Dam’s blood >3000 2585.75 ± 243.71 723.33 ± 297.14 ND
Amniotic ﬂuid ND 48.50 ± 65.48 ND ND
Table 2
Concentrations of dopamine (DA), γ-aminobutyric acid (GABA), glutamate (Glu), acetylcholine (ACh), noradrenaline (NA) and serotonin (5-HT) in fetal brains. Tissues were sampled 2 h
and 6 h after treatment of dams with LPS or SAL on E15 and E16. Data are presented as mean value ± SE (μg/g) and analyzed using Student’s t-test. *(p < 0.05) and t(p < 0.10)
relative to control at the given time point. Samples were taken from 3 dams per treatment at each time point.
Treatment/time point Neurotransmitter
DA GABA GLU ACH NA 5-HT
LPS
E15 (2 h)
0.14 ± 0.01 15.82 ± 0.71 543.88 ± 9.99 t 0.25 ± 0.10 10.12 ± 0.88 0.07 ± 0.00
SAL
E15 (2 h)
0.14 ± 0.01 16.64 ± 0.66 575.75 ± 15.77 0.28 ± 0.08 9.90 ± 0.87 0.08 ± 0.01
LPS
E15 (6 h)
0.11 ± 0.01 27.17 ± 3.49 * 567.04 ± 12.42* 0.12 ± 0.04 9.48 ± 0.50 0.06 ± 0.00
SAL
E15 (6 h)
0.10 ± 0.01 13.66 ± 1.33 624.90 ± 24.87 0.15 ± 0.06 8.70 ± 0.71 0.06 ± 0.00
LPS
E16 (2 h)
0.12 ± 0.01 15.36 ± 1.17 508.48 ± 27.77 0.24 ± 0.09 9.86 ± 0.79 0.06 ± 0.00
SAL
E16 (2 h)
0.11 ± 0.01 14.64 ± 1.78 540.62 ± 12.33 0.21 ± 0.09 9.74 ± 0.86 0.05 ± 0.00
LPS
E16 (6 h)
0.11 ± 0.00 16.74 ± 1.28 498.60 ± 13.69 0.19 ± 0.05 9.15 ± 0.49 0.06 ± 0.00
SAL
E16 (6 h)
0.11 ± 0.01 14.44 ± 5.31 515.28 ± 30.79 0.28 ± 0.11 8.98 ± 0.87 0.06 ± 0.01
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3.5. Cytokine determination in adult rat tissues
In blood and brain tissue samples of adult rats of both genders,
prenatally treated with LPS or SAL, no detectable levels of TNF-α and
IL-6 were found at P60.
3.6. Neurotransmitters quantiﬁcation in adult rat brain
Forty-eight two-way ANOVA calculations were conducted in total to
analyze eﬀects of LPS and MP-III-022 on each of six neurotransmitters
in each of four brain regions, separately for male and female rats at P60.
Only reports bearing signiﬁcant diﬀerences are presented in this sec-
tion. In male rats the LPS treatment induced a signiﬁcant increase in
Table 3
Total and estimated free brain concentrations of MP-III-022, dosed at 2.5 mg/kg, administered to pups. Data are presented as mean ± SEM (nmol/kg), n = 3.
Time point Total brain concentration Estimated free brain concentration
Males Females Males Females
20 min after 1 st dose 1408.64 ± 330.42 981.65 ± 285.25 93.11 ± 0.02 64.89 ± 0.02
24 h after 1 st dose 139.76 ± 70.27 38.95 ± 8.71 9.24 ± 0.01 2.57 ± 0.01
20 min after 3rd dose 1653.90 ± 696.19 517.77 ± 118.06 109.32 ± 0.05 34.22 ± 0.01
20 min after 7th dose 1318.81 ± 1119.20 345.53 ± 177.92 87.17 ± 0.07 22.84 ± 0.01
24 h after 7th dose 148.41 ± 8.55 216.03 ± 71.92 9.81 ± 0.01 14.28 ± 0.01
Fig. 2. Eﬀects of prenatal LPS (E15/16) and postnatal MP-III-022 (P21-28) treatments on distance traveled by female Wistar oﬀspring at P60. Activity was recorded during 30 min of
habituation and baseline activity (HAB trial), then 30 min after saline challenge (SAL trial) and ﬁnally 60 min after amphetamine (0.5 mg/kg, i.p.) administration (AMPH trial). Panel A:
the main eﬀects of between-subject factors (LPS and MP-III-022) in each trial, as analyzed by three-way RM ANOVA. Graphs B, C and D: pairwise multiple comparison
(Student–Newman–Keuls method) of LPS and MP-III-022 eﬀects on total distance traveled in each of three trials (HAB, SAL and AMPH, respectively). Graphs E and F: eﬀects of MP-III-022
on distance per time bin analyzed by pairwise multiple comparison procedures (Student–Newman–Keuls method) within SAL or LPS cohorts, respectively. Data (mean value ± SEM) are
shown as total distance per trial (B, C and D) or distance traveled in 10 min bins (E and F). *(p < 0.05) and **(p < 0.01). A trend denotes p values between 0.05 and 0.1.
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ACh concentration in striatum (F(18, 1) = 5.357, p = 0.033), and an
increase in glutamate concentration in ventral hippocampus (F(18, 1)
= 6.513, p = 0.020). In female rats the MP-III-022 treatment induced a
signiﬁcant decrease in ACh concentration in ventral hippocampus (F
(20, 1) = 6.533, p = 0.019). Concentrations of all neurotransmitters in
speciﬁc brain regions and signiﬁcant diﬀerences obtained in pairwise
multiple comparison procedure (SNK method) are presented in
Supplementary Table 2.
4. Discussion
This is the ﬁrst study that reports the changes of neurotransmitter
concentrations in rat fetal brain during LPS-induced MIA. We have
shown that LPS treatment at E15 induced an acute GABAergic/gluta-
matergic imbalance in fetal brain, followed further by both, a decreased
baseline locomotor activity and reactivity to amphetamine in adult
oﬀspring. Moreover, we report that repeated potentiation of
α5GABAARs in preadolescence prevented the deﬁcit in locomotor
response to amphetamine in adult LPS females.
4.1. Cytokine induction and GABA/glutamate imbalance
In the present study, LPS-induced MIA was conﬁrmed via detection
of TNF-α and IL-6 release in dams’ blood at the earliest time point after
immune challenge (E15, 2 h). To our knowledge, none of the published
studies on prenatal LPS exposure has assessed cytokine induction after
the second LPS dose, which is routinely administered used in similar
protocols. Here, the second LPS challenge, at E16, did not additionally
induce these cytokines in dams’ blood, and also, TNF-α elevation in the
placental tissue detected at E15 diminished gradually during the next
24 h. While there was no TNF-α elevation in amniotic ﬂuid or fetal
brains at any time point, IL-6 concentration in amniotic ﬂuid was in-
creased 6 h after LPS challenge at E15; unfortunately, the data on IL-6
concentration in fetal brain was uninterpreTable Such diﬀering ﬁndings
on these two pro-inﬂammatory cytokines in amniotic ﬂuid are not
surprising given a study in the human placental perfusion model
Fig. 3. Eﬀects of prenatal LPS (E15/16) and postnatal MP-III-022 (P21-28) treatments on distance traveled by male Wistar oﬀspring at P60. Activity was recorded during 30 min of
habituation and baseline activity (HAB trial), then 30 min after saline challenge (SAL trial) and ﬁnally 60 min after amphetamine (0.5 mg/kg, i.p.) administration (AMPH trial). Panel A:
the main eﬀects of between-subject factors (LPS and MP-III-022) in each trial, as analyzed by three-way RM ANOVA. Graphs B, C and D: pairwise multiple comparison
(Student–Newman–Keuls method) of LPS and MP-III-022 eﬀects on total distance traveled in each of three trials (HAB, SAL and AMPH, respectively). Graphs E and F: eﬀects of MP-III-022
on distance per time bin analyzed by pairwise multiple comparison procedures (Student–Newman–Keuls method) within SAL or LPS cohorts, respectively. Data (mean value ± SEM) are
shown as total distance per trial (B, C and D) or distance traveled in 10 min bins (E and F). *(p < 0.05). A trend denotes p values between 0.05 and 0.1.
B. Batinić et al. International Journal of Developmental Neuroscience 61 (2017) 31–39
36
showing that IL-6, but not TNF-α, exhibits substantial transfer to the
fetal circulation (Zaretsky et al., 2004).
It should be underlined that increased levels of cytokines in am-
niotic ﬂuid may as well derive from LPS-induced immune activation of
the membrane that surrounds the fetus during gestation, as discussed by
Gayle et al. (2004). Namely, the same dose of LPS (100 μg/kg, 0111:B4
serotype) administered to pregnant Sprague–Dawley dams, but at E18,
induced an increase in TNF-α and IL-6 concentrations in dams’ blood
and amniotic ﬂuid, and upregulated cytokine mRNA in both placenta
and chorioamnion, but not in the fetal brain (Gayle et al., 2004). In line
with the latter ﬁnding, TNF-α and IL-6 concentrations in fetal brain
were not signiﬁcantly changed 4 h after treatment with 50 μg/kg of LPS
(0111:B4 serotype) to Sprague–Dawley dams at E18 (Ashdown et al.,
2006). However, in a study with another LPS serotype (05:B55, from
Escherichia coli), administered to Sprague–Dawley dams at E15 at a
signiﬁcantly higher dose (250 μg/kg), both TNF-α and IL-6 were de-
tected in fetal brains and amniotic ﬂuid after 4 h, but their corre-
sponding concentrations in dams’ blood were more than 100-fold (for
TNF-α) or 5-fold (for IL-6) higher compared to our present report
(Oskvig et al., 2012). Thus, in our settings of less vigorous immune
activation, an increase of IL-6 in fetal brain around the second time
point at E15 cannot be excluded, especially having in mind that the
permeability of rat placental barrier to IL-6 is expected to be higher at
E15 than at E18 (Dahlgren et al., 2006).
Although we found no direct support for acute fetal neuroin-
ﬂammation, the surge of IL-6 in amniotic ﬂuid occurred concurrently
with a signiﬁcant GABAergic/glutamatergic imbalance in fetal brains. If
we put aside the probable involvement of other cytokines, and assume
that fetal brain was exposed to an increased concentration of IL-6 for a
short time, we may hypothesize that IL-6 elevation upregulated the
expression of neurotrophin-3 (März et al., 1999), which in turn was
reported to increase activity of GAD67, an enzyme that converts glu-
tamate to GABA (Pérez-Navarro et al., 1999). In the current experiment,
GABA concentration in fetal brain reached values twice higher in
comparison to control tissue, while glutamate concentration at the
same time point (E15, 6 h) was signiﬁcantly decreased, following a
statistical trend in concentration decrease observed as early as 2 h after
the LPS challenge. No additional imbalances of other main neuro-
transmitters in fetal brain were discovered, and concentrations of GABA
and glutamate were not aﬀected after the second LPS challenge at E16.
Bearing in mind that rat fetal brain develops at a very high rate, due
to the short gestation period, even a few hours of GABA/glutamate
imbalance at E15 might have been suﬃcient to protractedly aﬀect
numerous regulatory processes in the developing GABAergic system.
Here, attention should be given to α5GABAAR emergence in the de-
veloping hippocampus, which occurs at the very time of MIA onset and
GABA imbalance in the present study; namely, at E14 α5GABAARs are
absent, while by E17 they become abundant in hippocampus and fetal
cortex (Laurie et al., 1992). Interestingly, in a diﬀerent LPS challenge
protocol, among 3285 genes dysregulated just 4 h after LPS treatment,
Oskvig et al. (2012) observed a signiﬁcant down-regulation of genes for
both GAD67 and GAD65. While this ﬁnding may be seen as at odds with
a signiﬁcant embryonic GABA increase and glutamate decrease re-
vealed in our present study, one must notice major divergences between
these two MIA models. The diﬀerences in the rat strain, LPS serotype
and mostly LPS dosage regimen used may have resulted in a full-blown
immune response in the study by Oskvig et al. (2012).
Additionally, in the current study we looked for possible changes in
levels of analyzed cytokines and neurotransmitters in adult oﬀspring at
P60. An absence of detectable concentrations of TNF-α and IL-6 in adult
brain or blood suggests that our LPS exposed oﬀspring did not develop a
persistent inﬂammation, possibility of which was discussed in Meyer
et al. (2011). For comparison, increased cytokines in blood were de-
tected in adult LPS exposed animals, but in protocols substantially
diﬀerent from ours, which involved subcutaneous treatment with a
2 mg/kg dose of LPS (serotype 026:B6) daily (Romero et al., 2010), or
1 mg/kg dose of LPS (serotype 026:B6) on alternate days (Borrell et al.,
2002) during the whole period of rat pregnancy.
In the present experiment, a signiﬁcant increase of glutamate in
ventral hippocampus and acetylcholine in dorsal striatum was detected
in LPS males; it would by highly speculative to try and answer how
these ﬁndings may have aﬀected the behavioral output in the used
behavioral paradigm. Nonetheless, a signiﬁcant decrease of ACh de-
tected in the ventral hippocampus of MP-III-022-treated females sup-
ports at least partly the revealed tendency of decreased locomotor ac-
tivity in the habituation trial, considering that ACh release in the
ventral hippocampus correlates with an increased exploratory activity
(Bianchi et al., 2003).
4.2. Behavioral eﬀects of LPS
Our previous study showed that LPS treatment (100 μg/kg) at E15/
16 resulted in a signiﬁcant decrease of baseline locomotor activity as
well as reactivity to amphetamine (0.5 mg/kg) in Wistar female oﬀ-
spring at P60 (Batinić et al., 2016). Hereby, in an elaborate design,
involving a repeated administration during the fourth postnatal week of
the selected PAM at α5GABAARs or the corresponding solvent, we re-
plicated a signiﬁcant decrease of distance traveled in the habituation
and saline trials in the LPS-females, while the hyporeactivity to am-
phetamine reached a statistical trend in comparison to SAL females.
While concordant to each other, these two sets of our data are appar-
ently at odds with reports from two other studies which were also
conducted on Wistar rats and used LPS exposure protocol identical to
ours (Wischhof et al., 2015a, 2015b). In one study authors reported an
increased baseline locomotion in LPS females at P60, relative to con-
trols (Wischhof et al., 2015a), while in the other study no diﬀerence in
distance travelled between LPS and control females (P100-120) was
observed (Wischhof et al., 2015b). However, it needs to be emphasized
that these authors have reported a substantially higher overall activity,
at the levels of up to 35 m during the ﬁrst 5 min, and up to 200 m
during 60 min testing (Wischhof et al., 2015a), or around 350 m in just
30 min (Wischhof et al., 2015b); such oversized and inconsistent values
impede any comparison with the current results. On the other hand, in a
study conducted in 60 day old Sprague Dawley rats born to dams
treated with a 50 μg/kg dose of LPS at E15/16, a non-signiﬁcant de-
crease of baseline locomotion in LPS females during 60 min of re-
cording was observed, with absolute levels of activity corresponding
well to our data (Harvey and Boksa, 2014a).
Our previous ﬁndings on locomotor activity of adult males (without
any treatment in preadolescence), indicated a consistently lower loco-
motor activity of LPS vs. SAL rats in every time bin of each trial, with a
signiﬁcant decrease obtained in the second trial, after saline injection
stressor (Batinić et al., 2015). In the current study, locomotor activity of
LPS vs. SAL rats was signiﬁcantly decreased in the third (amphetamine)
trial, while a trend of hypolocomotion was observed in the ﬁrst (habi-
tuation) trial. The present set of results corresponds well with a sig-
niﬁcant reduction of baseline locomotion in adult, 60 days old Sprague-
Dawley males born to dams treated with 50 μg/kg of LPS on E15/16
(Harvey and Boksa, 2014a). Moreover, the same authors reported a
decreased locomotor reactivity of 70 day old LPS males during the ﬁrst
30 min after amphetamine (2 mg/kg) administration (Harvey and
Boksa, 2014b). Apart from these corresponding results, Wischhof et al.
(2015a, 2015b) reported no diﬀerence in baseline locomotion in their
studies in male rats; however, the above-discussed inconsistency of
absolute distance values applies to data obtained in males as well.
The detailed observations on behavioral eﬀects of prenatal LPS
admnistration in our MIA model may be summarized in a conclusion
that both female and male oﬀspring prenatally treated with 100 μg/kg
of LPS at E15/16 manifest analogous deﬁcits in baseline locomotor
activity and reactivity to amphetamine at their young adult age, and
that a matching deﬁcit can be observed after challenge with 50 μg/kg of
LPS at E15/16, at least in male Sprague Dawley rats (Harvey and Boksa,
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2014a, 2014b).
4.3. Behavioral eﬀects of positive modulation at α5GABAA receptors
According to the analysis of pharmacokinetic and electro-
physiological data presented in Stamenić et al. (2016), the ligand MP-
III-022 at doses 1–10 mg/kg, which correspond to mild via moderate to
strong potentiation at α5GABAARs not accompanied by any activity at
other subtypes of benzodiazepine-sensitive GABAARs, was devoid of
ataxic or sedative action, as assessed in the rotarod and spontaneous
locomotor activity test in rats, respectively. The results of our current
pharmacokinetic study in preadolescent rats have helped to choose the
dose of 2 mg/kg daily as appropriately selective for one-week admin-
istration in young rats. The major novelty we report here is that a re-
peated potentiation of α5GABAARs in early rat adolescence, from
postnatal day 22–28, prevented the later emergence of a deﬁcit in lo-
comotor response to amphetamine in LPS female oﬀspring at P60.
Otherwise, the hint of such hyporeactivity to amphetamine can be
traced back to the locomotor assay conducted at P40 in our previous
study (Batinić et al., 2015). Additionally, after the emergence of
GABAAα5Rs in fetal brain between E14 and E17 (Laurie et al., 1992),
the second critical period in their development can be broadly con-
nected with postnatal day 10 and 30 (Yu et al., 2006). Following that
observation we assumed that selective modulation of α5GABAARs ac-
tivity should take place before the period of adolescence.
The observed gender diﬀerence in the relative role of selective
modulation of α5GABAARs is a novel, but not an unexpected ﬁnding;
importantly, a number of gender diﬀerences in behavioral and elec-
trophysiological parameters related to the hippocampus have been
described (Monfort et al., 2015). Moreover, it has been demonstrated
that gender aﬀects persistent neuroinﬂammation, with GABAA re-
ceptors described as less active in females in these settings (Tonsfeldt
et al., 2016), which may be an indirect explanation for more useful
consequences of positive modulation of α5GABAARs in females than
males seen in the present study. Finally, it was recently found that both,
single and protracted treatment with another ligand selective for
α5GABAARs, structurally similar to, but less receptor subtype-selective
than MP-III-022, can produce a pattern of decreased stress-induced
behaviors across a battery of tests in female, but not in male mice ex-
posed to unpredictable chronic mild stress (Piantadosi et al., 2016).
However, for a more detailed conclusion in the current model, one
would need to perform studies of gene expression of α5GABAARs and
the electrophysiological activity of these receptors ex vivo.
4.4. Conclusion
Prenatal exposure to LPS is a common model of MIA with relevance
to schizophrenia and/or autism onset (Harvey and Boksa, 2012; Kirsten
et al., 2013). In contrast to the protocols of repeated exposure to the
eﬀects of high LPS doses during the whole pregnancy, which resulted in
a prolonged postnatal inﬂammation in oﬀspring (Borrell et al., 2002;
Romero et al., 2010), the present exposure to a low-to-moderate dose of
LPS resulted in one-day MIA with a delayed occurrence of behavioral
abnormalities, proving it as a translationally-realistic and replicable
neurodevelopmental model. Clinical trials of various psychotropic
drugs in adolescent subjects with schizophrenia prodrome (e.g.
Cornblatt et al., 2007) have prioritized the need for animal models
which enable investigation of early interventions and preventive
treatments (Meyer et al., 2010). Preclinical studies that introduced the
concept of peri-adolescent preventive treatment in prenatal PolyI:C
model of immune activation have reported that treatment with anti-
psychotic and/or antidepressant drugs successfully blocked some of
schizophrenia-related abnormalities (Meyer et al., 2010; Piontkewitz
et al., 2009). Within the research focusing on the role of GABA-ergic
system in the schizophrenia development (Schmidt and Mirnics, 2015),
the present ﬁnding on amelioration of at least some of adverse con-
sequences of MIA by pharmacological modulation of α5GABAARs ac-
tivity in preadolescence may indicate a new target in the strategy of
preventive treatments.
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